source
- Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease studyA new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competi…BioPharma Dive · 8d ago↗ source
- STAT+: Pharmalittle: We’re reading about Trump’s plan for tariffs on generics, a Merck and Gilead HIV pill, and morePresident Trump plans to impose tariffs on imported generic medicines, his latest threat aimed at bringing pharmaceutical manufacturing back to the U.S.STAT · 8d ago↗ source
- FDA Takes Further Steps to Remove Outdated Authorizations for Color Additives in FoodThe U.S. Food and Drug Administration today announced two actions targeting petroleum-based color additives in food, continuing the agency’s broader efforts to Make America Healthy Again.